ACUR Insider Trading Activity and SEC Form 4 Filings
ACUR insider trading summary
No open-market insider purchases or sales of Acura Pharmaceuticals, Inc (ACUR) have been reported on SEC Form 4 in the past 12 months.
Latest ACUR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 14, 2017 | Peter A Clemens | Senior VP and CFO | Buy | $30K (300,000 @ $0.10) |
| Dec 14, 2017 | Bruce F Wesson | Director | Buy | $34K (335,734 @ $0.10) |
| Dec 14, 2017 | Robert A Seiser | VP, Controller & Treasurer | Buy | $30K (300,000 @ $0.10) |
| Dec 14, 2017 | Robert B Jones | President and CEO | Buy | $40K (400,000 @ $0.10) |
| Dec 14, 2017 | Albert W Brzeczko | VP Technical Affairs - APT | Buy | $30K (300,000 @ $0.10) |
| Dec 14, 2017 | George K Ross | Director | Buy | $5K (50,000 @ $0.10) |
| Dec 14, 2017 | James F Emigh | VP Corporate Development | Buy | $40K (400,000 @ $0.10) |
| Dec 14, 2017 | William G Skelly | Director | Buy | $10K (100,000 @ $0.10) |
| Dec 14, 2017 | Galen Partners International III L P | Insider | Sell | $220K (2,195,734 @ $0.10) |
| Dec 14, 2017 | Galen Partners III L P | Insider | Sell | $220K (2,195,734 @ $0.10) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.